You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 6,221,847


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 6,221,847
Title: Composition and method for treating bacterial infection
Abstract:A method and composition for preventing and treating infection from clinically relevant bacterial isolates is disclosed. The composition contains an anti-bacterial agent that inhibits the growth of the bacteria, including members of both gram negative and gram positive isolates. In particular, the anti-bacterial agent comprises a bacteriocin produced by Propionibacterium. For instance, in one embodiment, the bacteriocin is produced by the B1264 strain of Propionibacterium jensenii.
Inventor(s): Barefoot; Susan F. (Liberty, SC), Ratnam; Priya (San Ramon, CA)
Assignee: Clemson University (Clemson, SC)
Application Number:09/313,752
Patent Claims:1. A method for treating a bacterial infection in a patient comprising:

administering to said patient a composition containing an anti-bacterial agent, said anti-bacterial agent comprising a bacteriocin produced by dairy propionibacteria selected from the group consisting of Propionibacterium jensenii, P. acidipropionici, P. freudenreichii subspecies freudenreichii and shermanii, P. thoenii, and combinations thereof, wherein said bacteriocin is administered in a therapeutically active dosage for a time effective to inhibit the growth of a bacterial isolate in said patient, said bacterial isolate comprising a member of the Enterobacteriaceae or a gram positive bacterium chosen from the group consisting of Listeria moncytogenes, Staphylococcus aureus, Listeria murrayi, and mixtures thereof.

2. A method according to claim 1, wherein said bacteriocin is produced by Propionibacterium jensenii.

3. A method according to claim 1, wherein said bacteriocin is produced by the B1264 strain of Propionibacterium jensenii.

4. A method according to claim 1, wherein said member of the Enterobacteriaceae is chosen from the group consisting of Escheriachia coli, Proteus vulgaris, Enterobacter aerogenes, Shigella flexneri, Salmonella typhimurium, Serratia marcescens and mixtures thereof.

5. A method according to claim 1, wherein said composition is administered via mucosal administration.

6. A method according to claim 1, wherein said composition is administered via parenteral administration.

7. A method according to claim 1, wherein said composition is administered within a delivery system.

8. A method according to claim 7, wherein said delivery system is a liposome.

9. A method according to claim 1, wherein said composition further comprises a pharmaceutically acceptable carrier.

10. A method according to claim 9, wherein said pharmaceutically acceptable carrier is chosen from the group consisting of physiological saline, dextrose, sterile water, and mixtures thereof.

11. A method according to claim 1, wherein said bacteriocin is administered in a therapeutically active dosage, for a time effective to kill the bacteria in said bacterial infection.

12. A method according to claim 11, wherein said therapeutically active dosage is in the range of about 100 .mu.g per kilogram of body weight per minute to about 200 g per kilogram of body weight per minute.

13. A method for treating a bacterial infection in a patient comprising:

administering to said patient a composition containing an anti-bacterial agent, said anti-bacterial agent comprising a bacteriocin produced by Propionibacterium jensenii, wherein said bacteriocin is administered in a therapeutically active dosage for a time effective to inhibit the growth of a bacterial isolate in said patient, said bacterial isolate comprising a member of the Enterobacteriaceae or a gram positive bacterium chosen from the group consisting of Listeria moncytogenes, Staphylococcus aureus, Listeria murrayi, and mixtures thereof.

14. A method according to claim 13, wherein said bacteriocin is produced by the B1264 strain of Propionibacterium jensenii.

15. A method according to claim 13, wherein said member of the Enterobacteriaceae is chosen from the group consisting of Escheriachia coli, Proteus vulgaris, Enterobacter aerogenes, Shigella flexneri, Salmonella typhimurium, Serratia marcescens and mixtures thereof.

16. A method according to claim 13, wherein said composition is administered via mucosal administration.

17. A method according to claim 13, wherein said composition is administered via parenteral administration.

18. A method according to claim 13, wherein said composition is administered within a delivery system.

19. A method according to claim 18, wherein said delivery system is a liposome.

20. A method according to claim 13, wherein said composition further comprises a pharmaceutically acceptable carrier.

21. A method according to claim 20, wherein said pharmaceutically acceptable carrier is chosen from the group consisting of physiological saline, dextrose, sterile water, and mixtures thereof.

22. A method according to claim 13, wherein said bacteriocin is administered in a therapeutically active dosage, for a time effective to kill the bacteria in said bacterial infection.

23. A method according to claim 22, wherein said therapeutically active dosage is in the range of about 100 .mu.g per kilogram of body weight per minute to about 200 g per kilogram of body weight per minute.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.